These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 29297039)

  • 21. Strategic options for brand-name prescription drugs when patents expire.
    Mehta SC; Mehta SS
    Health Mark Q; 1997; 14(3):107-14. PubMed ID: 10167309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prices, profits, and innovation: examining criticisms of new psychotropic drugs' value.
    Huskamp HA
    Health Aff (Millwood); 2006; 25(3):635-46. PubMed ID: 16684726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Eleventh Circuit holds that agreements in which pharmaceutical companies pay generic companies not to compete may be valid.
    Garrigues A
    J Law Med Ethics; 2004; 32(1):181-4. PubMed ID: 15152443
    [No Abstract]   [Full Text] [Related]  

  • 24. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
    Panattoni LE
    J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The diffusion of generics after patent expiry in Germany.
    Fischer KE; Stargardt T
    Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Who Needs XR, LA, SR, XL, ER, or CR?
    Curtiss FR
    J Manag Care Pharm; 2005; 11(9):772-3, 775-6. PubMed ID: 16300421
    [No Abstract]   [Full Text] [Related]  

  • 28. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 29. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States.
    Jones GH; Carrier MA; Silver RT; Kantarjian H
    Blood; 2016 Mar; 127(11):1398-402. PubMed ID: 26817958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. White paper. The five myths of generic competition. A Pharma Matters report. March 2009.
    Drug News Perspect; 2009 Apr; 22(3):171-5. PubMed ID: 19440560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
    Sarpatwari A; Kesselheim AS
    PLoS Med; 2016 Feb; 13(2):e1001955. PubMed ID: 26859662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Competition body rules that drug companies "abused" their position.
    Sidley P
    BMJ; 2003 Oct; 327(7421):946. PubMed ID: 14576226
    [No Abstract]   [Full Text] [Related]  

  • 34. Teva v. Eisai: what's the real "controversy"?
    Wang GL
    Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Free trade agreements make the drugs more expensive].
    Jeppsson A
    Lakartidningen; 2009 Nov 18-24; 106(47):3181. PubMed ID: 20082499
    [No Abstract]   [Full Text] [Related]  

  • 36. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
    Sinha MS; Curfman GD; Carrier MA
    JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
    [No Abstract]   [Full Text] [Related]  

  • 37. Going over the patent cliff.
    Schommer JC
    Minn Med; 2011 Oct; 94(10):42-3. PubMed ID: 23256283
    [No Abstract]   [Full Text] [Related]  

  • 38. India: access to affordable drugs and the right to health.
    Grover A; Citro B
    Lancet; 2011 Mar; 377(9770):976-7. PubMed ID: 21227487
    [No Abstract]   [Full Text] [Related]  

  • 39. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry.
    Brockmeier MS
    Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564
    [No Abstract]   [Full Text] [Related]  

  • 40. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.